Get the Stockscreener App
330.65
0.72%
-2.28
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $330.65, with a volume of 762.14K.
It is down -0.72% in the last 24 hours and down -4.32% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$332.93
Open:
$332.46
24h Volume:
762.14K
Relative Volume:
0.29
Market Cap:
$178.02B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
25.56
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
-0.26%
1M Performance:
-4.32%
6M Performance:
+19.27%
1Y Performance:
+25.84%
1-Day Range:
$330.20
$333.50
1-Week Range:
$328.07
$334.38
52-Week Range:
$257.05
$346.38
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
330.60 | 179.28B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,083.55 | 964.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
208.24 | 500.24B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
231.58 | 406.46B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.97 | 267.06B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.95 | 265.03B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Amgen Inc. $AMGN Shares Acquired by SS&H Financial Advisors Inc. - MarketBeat
Amgen Inc. Stock (AMGN) Opinions on 2025 Revenue Guidance and Drug Sales - Quiver Quantitative
Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co. - MarketBeat
Carnegie Investment Counsel Has $30.27 Million Stake in Amgen Inc. $AMGN - MarketBeat
Can Amgen Sustain Its Rally In 2026 (NASDAQ:AMGN) - Seeking Alpha
Check out Amgen's stock price (AMGN-CA) in real time - CNBC
Amgen Inc. $AMGN Stake Reduced by Pacer Advisors Inc. - MarketBeat
Avanza Fonder AB Purchases 4,546 Shares of Amgen Inc. $AMGN - MarketBeat
Does FDA’s UPLIZNA gMG Expansion Reshape the Bull Case for Amgen’s Diversification Story (AMGN)? - simplywall.st
Brookstone Capital Management Acquires 16,042 Shares of Amgen Inc. $AMGN - MarketBeat
Farther Finance Advisors LLC Buys 3,158 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Alpine Woods Capital Investors LLC - MarketBeat
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know - The Globe and Mail
Swedbank AB Sells 283,479 Shares of Amgen Inc. $AMGN - MarketBeat
Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 73% Return On Equity? - Yahoo Finance
Amgen Inc. $AMGN Shares Bought by Global X Japan Co. Ltd. - MarketBeat
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice? - The Globe and Mail
Revolve Wealth Partners LLC Sells 12,066 Shares of Amgen Inc. $AMGN - MarketBeat
Exchange Traded Concepts LLC Has $17.78 Million Position in Amgen Inc. $AMGN - MarketBeat
Is There Still Value in Amgen After Its Strong 2025 Share Price Run? - simplywall.st
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know - sharewise.com
Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open - ts2.tech
Fitch upgrades Amgen to ’BBB+’ on improved financial structure By Investing.com - Investing.com Nigeria
Fitch upgrades Amgen to ’BBB+’ on improved financial structure - Investing.com
Fitch raises Amgen credit rating, outlook stable - breakingthenews.net
Our Workforce - Amgen
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025 - ts2.tech
Amgen’s Long-Term Pediatric Psoriasis Study on Apremilast: Why the Latest Update Matters for Investors - TipRanks
Amgen’s Pediatric Inebilizumab Study Signals Long-Term Upside in Rare Autoimmune Disease - TipRanks
Matrix Asset Advisors Inc. NY Purchases 4,633 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc (NASDAQ:AMGN) Nasdaq Index Biotechnology Leadership Focus - Kalkine Media
Amgen Inc. (NASDAQ:AMGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amgen (AMGN) price target trimmed at Morgan Stanley as policy risks ease - MSN
Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025) - ts2.tech
Assessing Amgen (AMGN) Valuation After UPLIZNA Approval and New U.S. Drug Pricing Agreements - simplywall.st
The Best Dividend ETF to Buy: SCHD Pays a High Yield While VIG Focuses on Dividend Growth - The Motley Fool
Sarasin & Partners LLP Buys 47,873 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Foster Victor Wealth Advisors LLC - MarketBeat
Signal Advisors Wealth LLC Has $867,000 Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by CHICAGO TRUST Co NA - MarketBeat
Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts - ts2.tech
Voya Investment Management LLC Sells 275,398 Shares of Amgen Inc. $AMGN - MarketBeat
Bartlett & CO. Wealth Management LLC Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal - Benzinga
Has Amgen’s 26% Rally in 2025 Already Priced In Its Obesity and Oncology Ambitions? - Yahoo Finance
Is Amgen Inc. stock a top momentum playWeekly Stock Summary & Daily Stock Trend Watchlist - ulpravda.ru
Amgen to Cut US Drug Prices, Expand Patient Access - marketscreener.com
Amgen takes action with U.S. government to lower medicine costs By Investing.com - ca.investing.com
Amgen says Aimovig & Amjevita to be available at discounted monthly price of $299 under deal with U.S. govt - marketscreener.com
Amgen (AMGN) Moves to Reduce Drug Prices in Collaboration with U - GuruFocus
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
0.11%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):